首页 > 最新文献

Cancer treatment and research最新文献

英文 中文
Hepatocellular Carcinoma: Surgical Management and Evolving Therapies. 肝细胞癌:手术治疗和不断发展的疗法。
Q2 Medicine Pub Date : 2024-01-01 DOI: 10.1007/978-3-031-61238-1_10
Emanuel Eguia, Talia Baker, Marshall Baker

Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the eighth most common cancer in women worldwide. It is also the second leading cause of cancer death worldwide, with 780,000 deaths in 2018. Seventy-two percent of HCC cases occur in Asia, 10% in Europe, 8% in Africa, 5% in North America, and 5% in Latin America (Singal et al. in J Hepatol 72(2):250-261, 2020 [1]).

肝细胞癌(HCC)是全球男性第五大最常见癌症,女性第八大最常见癌症。它也是全球第二大癌症死因,2018年有78万人死于此病。72%的 HCC 病例发生在亚洲,10%发生在欧洲,8%发生在非洲,5%发生在北美,5%发生在拉丁美洲(Singal 等人,载于《J Hepatol》72(2):250-261,2020 [1])。
{"title":"Hepatocellular Carcinoma: Surgical Management and Evolving Therapies.","authors":"Emanuel Eguia, Talia Baker, Marshall Baker","doi":"10.1007/978-3-031-61238-1_10","DOIUrl":"https://doi.org/10.1007/978-3-031-61238-1_10","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the eighth most common cancer in women worldwide. It is also the second leading cause of cancer death worldwide, with 780,000 deaths in 2018. Seventy-two percent of HCC cases occur in Asia, 10% in Europe, 8% in Africa, 5% in North America, and 5% in Latin America (Singal et al. in J Hepatol 72(2):250-261, 2020 [1]).</p>","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"192 ","pages":"185-206"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathologic Features of Esophageal and Gastric Malignancies. 食管和胃恶性肿瘤的病理特征。
Q2 Medicine Pub Date : 2024-01-01 DOI: 10.1007/978-3-031-61238-1_2
Sanaa Al-Nattah, Eduard Matkovic, Michael Schwalbe, Kristina A Matkowskyj

Esophageal cancer is the eighth most common cancer globally, affecting approximately 570,000 people worldwide and currently ranking sixth among cancer-related mortality (Uhlenhopp et al. in, Clin J Gastroenterol 13:1010-1021, 2020). The prognosis is poor as many patients present with locally incurable or metastatic disease. In spite of advancements in treatment, the overall 5-year survival rates are in the realm of 10% whereas the 5-year post-esophagectomy survival rates are in the realm of 15-40% [2]. The incidence rates vary dramatically worldwide, which can be attributed to demographic and socioeconomic factors. Although the vast majority of esophageal neoplasms arise from the epithelial layer and include squamous cell carcinoma (SCC) and adenocarcinoma (AC), a subset of neuroendocrine and soft tissue tumors can also occur in the esophagus. Several tasks are presented to the surgical pathologist when dealing with esophageal carcinoma that include rendering a diagnosis, classifying the histological type, and assessing prognostic factors. This narrative review aims to evaluate current literature on various esophageal neoplasms and highlight pathological factors that impact clinical decision making and prognosis.

食管癌是全球第八大常见癌症,全球约有 57 万人罹患食管癌,目前在癌症相关死亡率中排名第六(Uhlenhopp 等人,Clin J Gastroenterol 13:1010-1021, 2020)。由于许多患者出现局部无法治愈或转移性疾病,因此预后很差。尽管治疗手段不断进步,但总体 5 年生存率仅为 10%,而食管切除术后 5 年生存率仅为 15-40%[2]。全世界的发病率差异巨大,这可能与人口和社会经济因素有关。虽然绝大多数食管肿瘤来自上皮层,包括鳞状细胞癌(SCC)和腺癌(AC),但也有一部分神经内分泌肿瘤和软组织肿瘤可能发生在食管。手术病理学家在处理食管癌时需要完成多项任务,包括做出诊断、划分组织学类型和评估预后因素。这篇叙述性综述旨在评估当前有关各种食管肿瘤的文献,并强调影响临床决策和预后的病理因素。
{"title":"Pathologic Features of Esophageal and Gastric Malignancies.","authors":"Sanaa Al-Nattah, Eduard Matkovic, Michael Schwalbe, Kristina A Matkowskyj","doi":"10.1007/978-3-031-61238-1_2","DOIUrl":"https://doi.org/10.1007/978-3-031-61238-1_2","url":null,"abstract":"<p><p>Esophageal cancer is the eighth most common cancer globally, affecting approximately 570,000 people worldwide and currently ranking sixth among cancer-related mortality (Uhlenhopp et al. in, Clin J Gastroenterol 13:1010-1021, 2020). The prognosis is poor as many patients present with locally incurable or metastatic disease. In spite of advancements in treatment, the overall 5-year survival rates are in the realm of 10% whereas the 5-year post-esophagectomy survival rates are in the realm of 15-40% [2]. The incidence rates vary dramatically worldwide, which can be attributed to demographic and socioeconomic factors. Although the vast majority of esophageal neoplasms arise from the epithelial layer and include squamous cell carcinoma (SCC) and adenocarcinoma (AC), a subset of neuroendocrine and soft tissue tumors can also occur in the esophagus. Several tasks are presented to the surgical pathologist when dealing with esophageal carcinoma that include rendering a diagnosis, classifying the histological type, and assessing prognostic factors. This narrative review aims to evaluate current literature on various esophageal neoplasms and highlight pathological factors that impact clinical decision making and prognosis.</p>","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"192 ","pages":"19-48"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathologic Features of Primary Pancreatic Malignancies. 原发性胰腺恶性肿瘤的病理特征。
Q2 Medicine Pub Date : 2024-01-01 DOI: 10.1007/978-3-031-61238-1_5
Tarek Abi-Saab, Ashley M Cunningham, Patrick S Rush, Kristina A Matkowskyj

This chapter explores the pathologic features of benign and malignant lesions of the pancreas. As pathologic classifications evolve particularly for cystic lesions and neuroendocrine tumors, it is important for physicians who treat patients with gastrointestinal malignance to fully evaluate these pathologic classifications.

本章探讨了胰腺良性和恶性病变的病理特征。随着病理分类的发展,尤其是囊性病变和神经内分泌肿瘤的病理分类,治疗胃肠道恶性肿瘤患者的医生必须全面评估这些病理分类。
{"title":"Pathologic Features of Primary Pancreatic Malignancies.","authors":"Tarek Abi-Saab, Ashley M Cunningham, Patrick S Rush, Kristina A Matkowskyj","doi":"10.1007/978-3-031-61238-1_5","DOIUrl":"https://doi.org/10.1007/978-3-031-61238-1_5","url":null,"abstract":"<p><p>This chapter explores the pathologic features of benign and malignant lesions of the pancreas. As pathologic classifications evolve particularly for cystic lesions and neuroendocrine tumors, it is important for physicians who treat patients with gastrointestinal malignance to fully evaluate these pathologic classifications.</p>","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"192 ","pages":"89-117"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutritional Genomics and Cancer Prevention. 营养基因组学与癌症预防。
Q2 Medicine Pub Date : 2024-01-01 DOI: 10.1007/978-3-031-55622-7_9
Shaista Aslam, Riffat Iqbal, Rida Fatima Saeed, Nuzhat Akram, Farhat Ijaz, Irfana Liaqat, Ahmed Sohaib Aslam

The scientific innovations have emphasized the importance of diet for one's health and wellbeing. The genetic revolution has enhanced our understanding about the effect of nutrients on genomic and transcriptomic profiles and gene-nutrition interactions (nutritional genomics). Furthermore, the contribution of micronutrient insufficiencies and macronutrient excess is evident in the development and progression of many diseases, especially cancer. It is speculated that nutrients have capacity to implicitly affect the physiological and pathophysiological processes via gene expression various regulatory processes. Moreover, the nutrients are known to affect the cellular networks involved in cancer progression and cancer inhibitory mechanisms targeting apoptosis or impaired angiogenesis. The interplay of regulatory processes in physiological systems and nutrients provides basis for the nutrigenomics. The functional genomics data further argue that cellular and molecular processes involved in the cancer progression are possibly programed genes during early development which may persist into adulthood and become detrimental. The incorporation of the functional interactions between nutrients and the genome has revolutionized the field of personalized medicine and provided the foundation for targeted cancer therapy through nutrients. There is growing evidence on the beneficial impacts of eating habits on lowering the risk of cancer, even if it can be difficult to pinpoint the precise role of nutrients. The nutrigenomic information may provide bases to develop disease prevention and treatment via nutrition, at the molecular level.

科学创新强调了饮食对人的健康和福祉的重要性。基因革命提高了我们对营养素对基因组和转录组特征的影响以及基因与营养相互作用(营养基因组学)的认识。此外,微量营养素不足和宏量营养素过剩在许多疾病,尤其是癌症的发生和发展中的作用显而易见。据推测,营养素能够通过基因表达的各种调控过程对生理和病理生理过程产生隐性影响。此外,众所周知,营养素会影响涉及癌症进展的细胞网络,以及针对细胞凋亡或血管生成受损的癌症抑制机制。生理系统和营养素的调控过程之间的相互作用为营养基因组学提供了基础。功能基因组学数据进一步论证了癌症进展所涉及的细胞和分子过程可能是早期发育过程中的程序基因,这些基因可能会持续到成年期并变得有害。营养素与基因组之间的功能性相互作用已经彻底改变了个性化医疗领域,并为通过营养素进行癌症靶向治疗奠定了基础。越来越多的证据表明,饮食习惯对降低癌症风险有好处,尽管营养素的确切作用可能难以确定。营养基因组学信息可在分子水平上为通过营养来预防和治疗疾病提供依据。
{"title":"Nutritional Genomics and Cancer Prevention.","authors":"Shaista Aslam, Riffat Iqbal, Rida Fatima Saeed, Nuzhat Akram, Farhat Ijaz, Irfana Liaqat, Ahmed Sohaib Aslam","doi":"10.1007/978-3-031-55622-7_9","DOIUrl":"https://doi.org/10.1007/978-3-031-55622-7_9","url":null,"abstract":"<p><p>The scientific innovations have emphasized the importance of diet for one's health and wellbeing. The genetic revolution has enhanced our understanding about the effect of nutrients on genomic and transcriptomic profiles and gene-nutrition interactions (nutritional genomics). Furthermore, the contribution of micronutrient insufficiencies and macronutrient excess is evident in the development and progression of many diseases, especially cancer. It is speculated that nutrients have capacity to implicitly affect the physiological and pathophysiological processes via gene expression various regulatory processes. Moreover, the nutrients are known to affect the cellular networks involved in cancer progression and cancer inhibitory mechanisms targeting apoptosis or impaired angiogenesis. The interplay of regulatory processes in physiological systems and nutrients provides basis for the nutrigenomics. The functional genomics data further argue that cellular and molecular processes involved in the cancer progression are possibly programed genes during early development which may persist into adulthood and become detrimental. The incorporation of the functional interactions between nutrients and the genome has revolutionized the field of personalized medicine and provided the foundation for targeted cancer therapy through nutrients. There is growing evidence on the beneficial impacts of eating habits on lowering the risk of cancer, even if it can be difficult to pinpoint the precise role of nutrients. The nutrigenomic information may provide bases to develop disease prevention and treatment via nutrition, at the molecular level.</p>","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"191 ","pages":"217-244"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutrition and Dietary Intervention in Cancer: Gaps, Challenges, and Future Perspectives. 癌症的营养和膳食干预:差距、挑战和未来展望。
Q2 Medicine Pub Date : 2024-01-01 DOI: 10.1007/978-3-031-55622-7_11
Falak Zeb, Aqsa Mehreen, Huma Naqeeb, Muneeb Ullah, Afraa Waleed, Uzma Azeem Awan, Adnan Haider, Muhammad Naeem

The term "cancer" refers to the state in which cells in the body develop mutations and lose control over their replication. Malignant cancerous cells invade in various other tissue sites of the body. Chemotherapy, radiation, and surgery are the first-line modalities for the majority of solid cancers. These treatments work by mitigating the DNA damage of cancerous cells, but they can also cause harm to healthy cells. These side effects might be immediate or delayed, and they can cause a high rate of morbidity and mortality. Dietary interventions have a profound impact on whole-body metabolism, including immunometabolism and oncometabolism which have been shown to reduce cancer growth, progression, and metastasis in many different solid tumor models with promising outcomes in early phase clinical studies. Dietary interventions can improve oncologic or quality-of-life outcomes for patients that are undergoing chemotherapy or radiotherapy. In this chapter, we will focus on the impact of nutritional deficiencies, several dietary interventions and their proposed mechanisms which are used as a novel therapy in controlling and managing cancers.

癌症 "一词是指人体细胞发生突变并失去复制控制的状态。恶性癌细胞会侵入人体其他各个组织部位。化疗、放疗和手术是治疗大多数实体癌的一线方法。这些疗法通过减轻癌细胞的 DNA 损伤发挥作用,但也会对健康细胞造成伤害。这些副作用可能是直接的,也可能是延迟的,而且会导致很高的发病率和死亡率。膳食干预对全身代谢,包括免疫代谢和肿瘤代谢有深远影响,在许多不同的实体肿瘤模型中,膳食干预已被证明可以减少癌症的生长、恶化和转移,早期临床研究结果令人鼓舞。饮食干预可以改善正在接受化疗或放疗的患者的肿瘤治疗效果或生活质量。在本章中,我们将重点介绍营养缺乏的影响、几种膳食干预措施及其作为控制和管理癌症的新疗法的拟议机制。
{"title":"Nutrition and Dietary Intervention in Cancer: Gaps, Challenges, and Future Perspectives.","authors":"Falak Zeb, Aqsa Mehreen, Huma Naqeeb, Muneeb Ullah, Afraa Waleed, Uzma Azeem Awan, Adnan Haider, Muhammad Naeem","doi":"10.1007/978-3-031-55622-7_11","DOIUrl":"https://doi.org/10.1007/978-3-031-55622-7_11","url":null,"abstract":"<p><p>The term \"cancer\" refers to the state in which cells in the body develop mutations and lose control over their replication. Malignant cancerous cells invade in various other tissue sites of the body. Chemotherapy, radiation, and surgery are the first-line modalities for the majority of solid cancers. These treatments work by mitigating the DNA damage of cancerous cells, but they can also cause harm to healthy cells. These side effects might be immediate or delayed, and they can cause a high rate of morbidity and mortality. Dietary interventions have a profound impact on whole-body metabolism, including immunometabolism and oncometabolism which have been shown to reduce cancer growth, progression, and metastasis in many different solid tumor models with promising outcomes in early phase clinical studies. Dietary interventions can improve oncologic or quality-of-life outcomes for patients that are undergoing chemotherapy or radiotherapy. In this chapter, we will focus on the impact of nutritional deficiencies, several dietary interventions and their proposed mechanisms which are used as a novel therapy in controlling and managing cancers.</p>","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"191 ","pages":"281-307"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modern Treatment Strategies for Borderline Resectable Pancreatic Cancer. 边界可切除胰腺癌的现代治疗策略。
Q2 Medicine Pub Date : 2024-01-01 DOI: 10.1007/978-3-031-61238-1_4
Dominic Vitello, Mark S Talamonti

Pancreatic ductal adenocarcinoma (PDAC) continues to be a daunting clinical challenge. In 2023, it is estimated that 64,000 people will be newly diagnosed with PDAC and 51,000 people will die from PDAC. By 2030, PDAC is predicted to be the second leading cause of cancer-related death, second only to lung cancer (Siegel et al in, CA Cancer J Clin 73(1):17-48, 2023). It is a disease characterized by its late presentation, rapid demise thereafter, and, until recently, relatively ineffective systemic therapies. Despite this grim prognosis, appreciable progress has been made in the identification of patients with localized disease, who may be candidates for potentially curative resections, and in the understanding of the technical nuances and efficacy of aggressive surgical procedures. Currently, the overall 5-year survival rate is 15-25% for patients who undergo resection and receive adjuvant chemotherapy with or without chemoradiation therapy.

胰腺导管腺癌(PDAC)仍然是一项严峻的临床挑战。据估计,2023 年将有 64,000 人新确诊为 PDAC,51,000 人死于 PDAC。预计到 2030 年,PDAC 将成为癌症相关死亡的第二大原因,仅次于肺癌(Siegel et al in, CA Cancer J Clin 73(1):17-48, 2023)。这种疾病的特点是发病较晚,随后迅速死亡,而且直到最近,系统疗法的效果还相对较差。尽管预后不佳,但在识别可能接受根治性切除术的局部疾病患者方面,以及在了解积极外科手术的技术细节和疗效方面,已经取得了显著进展。目前,接受切除术并接受辅助化疗和或不接受化放疗的患者的 5 年总生存率为 15%-25%。
{"title":"Modern Treatment Strategies for Borderline Resectable Pancreatic Cancer.","authors":"Dominic Vitello, Mark S Talamonti","doi":"10.1007/978-3-031-61238-1_4","DOIUrl":"https://doi.org/10.1007/978-3-031-61238-1_4","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) continues to be a daunting clinical challenge. In 2023, it is estimated that 64,000 people will be newly diagnosed with PDAC and 51,000 people will die from PDAC. By 2030, PDAC is predicted to be the second leading cause of cancer-related death, second only to lung cancer (Siegel et al in, CA Cancer J Clin 73(1):17-48, 2023). It is a disease characterized by its late presentation, rapid demise thereafter, and, until recently, relatively ineffective systemic therapies. Despite this grim prognosis, appreciable progress has been made in the identification of patients with localized disease, who may be candidates for potentially curative resections, and in the understanding of the technical nuances and efficacy of aggressive surgical procedures. Currently, the overall 5-year survival rate is 15-25% for patients who undergo resection and receive adjuvant chemotherapy with or without chemoradiation therapy.</p>","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"192 ","pages":"67-88"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Histone Readers and Their Roles in Cancer. 组蛋白阅读器及其在癌症中的作用
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-45654-1_8
Hong Wen, Xiaobing Shi

Histone proteins in eukaryotic cells are subjected to a wide variety of post-translational modifications, which are known to play an important role in the partitioning of the genome into distinctive compartments and domains. One of the major functions of histone modifications is to recruit reader proteins, which recognize the epigenetic marks and transduce the molecular signals in chromatin to downstream effects. Histone readers are defined protein domains with well-organized three-dimensional structures. In this Chapter, we will outline major histone readers, delineate their biochemical and structural features in histone recognition, and describe how dysregulation of histone readout leads to human cancer.

真核细胞中的组蛋白受到多种多样的翻译后修饰,众所周知,这些修饰在将基因组划分为不同的区段和域方面发挥着重要作用。组蛋白修饰的主要功能之一是招募阅读蛋白,阅读蛋白能识别表观遗传标记,并将染色质中的分子信号转导到下游效应。组蛋白阅读器是具有组织良好的三维结构的定义蛋白质域。在本章中,我们将概述主要的组蛋白阅读器,描述它们在组蛋白识别中的生化和结构特征,并介绍组蛋白读出失调如何导致人类癌症。
{"title":"Histone Readers and Their Roles in Cancer.","authors":"Hong Wen, Xiaobing Shi","doi":"10.1007/978-3-031-45654-1_8","DOIUrl":"10.1007/978-3-031-45654-1_8","url":null,"abstract":"<p><p>Histone proteins in eukaryotic cells are subjected to a wide variety of post-translational modifications, which are known to play an important role in the partitioning of the genome into distinctive compartments and domains. One of the major functions of histone modifications is to recruit reader proteins, which recognize the epigenetic marks and transduce the molecular signals in chromatin to downstream effects. Histone readers are defined protein domains with well-organized three-dimensional structures. In this Chapter, we will outline major histone readers, delineate their biochemical and structural features in histone recognition, and describe how dysregulation of histone readout leads to human cancer.</p>","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"190 ","pages":"245-272"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11395558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138797741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decision-Making When Diagnostic Testing is Available. 诊断测试可用时的决策。
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-37993-2_4
Benjamin Djulbegovic, Iztok Hozo

When a decision-maker has the option of diagnostic testing, they face a typical dilemma: (1) do not administer treatment and do not test, (2) test and decide to administer treatment based on the test result, and (3) administer treatment without testing. In this chapter, we will discuss the theory behind threshold modeling when diagnostic testing is available; we will illustrate the approach by presenting a case vignette.

当决策者可以选择诊断测试时,他们会面临一个典型的困境:(1)不进行治疗也不进行测试,(2)根据测试结果进行测试并决定进行治疗,以及(3)在没有测试的情况下进行治疗。在本章中,当诊断测试可用时,我们将讨论阈值建模背后的理论;我们将通过一个案例小插曲来说明这种方法。
{"title":"Decision-Making When Diagnostic Testing is Available.","authors":"Benjamin Djulbegovic,&nbsp;Iztok Hozo","doi":"10.1007/978-3-031-37993-2_4","DOIUrl":"https://doi.org/10.1007/978-3-031-37993-2_4","url":null,"abstract":"<p><p>When a decision-maker has the option of diagnostic testing, they face a typical dilemma: (1) do not administer treatment and do not test, (2) test and decide to administer treatment based on the test result, and (3) administer treatment without testing. In this chapter, we will discuss the theory behind threshold modeling when diagnostic testing is available; we will illustrate the approach by presenting a case vignette.</p>","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"189 ","pages":"53-65"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41105204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence and Decision-Making. 证据和决策。
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-37993-2_1
Benjamin Djulbegovic, Iztok Hozo

Today, every country struggles to provide adequate health care to its citizens. Globally, an average of $8.3 trillion or 10% of gross domestic product (GDP) is annually spent on health services. In 2019, the USA spent nearly 18% ($3.2 trillion) of its GDP on health care, projected to reach $6.2 trillion by 2028.

今天,每个国家都在努力为其公民提供足够的医疗保健。在全球范围内,每年平均有8.3万亿美元或国内生产总值的10%用于医疗服务。2019年,美国将其GDP的近18%(3.2万亿美元)用于医疗保健,预计到2028年将达到6.2万亿美元。
{"title":"Evidence and Decision-Making.","authors":"Benjamin Djulbegovic,&nbsp;Iztok Hozo","doi":"10.1007/978-3-031-37993-2_1","DOIUrl":"https://doi.org/10.1007/978-3-031-37993-2_1","url":null,"abstract":"<p><p>Today, every country struggles to provide adequate health care to its citizens. Globally, an average of $8.3 trillion or 10% of gross domestic product (GDP) is annually spent on health services. In 2019, the USA spent nearly 18% ($3.2 trillion) of its GDP on health care, projected to reach $6.2 trillion by 2028.</p>","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"189 ","pages":"1-24"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41109138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Greek Orthodox. 希腊东正教。
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.1007/978-3-031-29923-0_15
Heather N Bitar

There are approximately 300 million members of the Greek Orthodox Church worldwide. It is the second-largest Christian church. Followers of this religion believe in eternal life. Thus, the church strongly emphasizes a positive outcome in death- "the deceased is alive with God." God is believed to be the healer of our souls and bodies, which is facilitated through prayer and participation in the life of the Church. Traditional medical interventions are generally accepted. Artificial life support is justifiable only when it offers a hope for meaningful recovery. Just as death should not be hastened, the natural dying process should not be prolonged. Timely advance care planning and early treatment goals discussions to help understand how the patient would define quality of life is paramount to setting limitations on what could be considered as nonbeneficial care. The medical team should not assume that all patients of the Greek Orthodox faith will feel the same around end-of-life beliefs and practices. This chapter aims to identify common themes and the historical contextual framework that may influence the way in which medical decision making is made by those who specifically subscribe to the Greek Orthodox faith.

全世界约有3亿希腊东正教会成员。它是第二大基督教会。这种宗教的信徒相信永生。因此,教会强烈强调死亡的积极结果——“死者与上帝同在。”上帝被认为是我们灵魂和身体的治愈者,这是通过祈祷和参与教会生活来促进的。传统的医疗干预措施被普遍接受。只有当人工生命支持为有意义的康复带来希望时,它才是合理的。正如死亡不应加速一样,自然死亡过程也不应延长。及时提前进行护理规划和早期治疗目标讨论,以帮助了解患者如何定义生活质量,这对于限制非有效护理至关重要。医疗团队不应认为所有信奉希腊东正教的患者在临终信仰和实践中都会有同样的感受。本章旨在确定共同的主题和历史背景框架,这些主题和框架可能会影响那些特别信奉希腊东正教的人做出医疗决策的方式。
{"title":"Greek Orthodox.","authors":"Heather N Bitar","doi":"10.1007/978-3-031-29923-0_15","DOIUrl":"10.1007/978-3-031-29923-0_15","url":null,"abstract":"<p><p>There are approximately 300 million members of the Greek Orthodox Church worldwide. It is the second-largest Christian church. Followers of this religion believe in eternal life. Thus, the church strongly emphasizes a positive outcome in death- \"the deceased is alive with God.\" God is believed to be the healer of our souls and bodies, which is facilitated through prayer and participation in the life of the Church. Traditional medical interventions are generally accepted. Artificial life support is justifiable only when it offers a hope for meaningful recovery. Just as death should not be hastened, the natural dying process should not be prolonged. Timely advance care planning and early treatment goals discussions to help understand how the patient would define quality of life is paramount to setting limitations on what could be considered as nonbeneficial care. The medical team should not assume that all patients of the Greek Orthodox faith will feel the same around end-of-life beliefs and practices. This chapter aims to identify common themes and the historical contextual framework that may influence the way in which medical decision making is made by those who specifically subscribe to the Greek Orthodox faith.</p>","PeriodicalId":9486,"journal":{"name":"Cancer treatment and research","volume":"187 ","pages":"219-229"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41232546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer treatment and research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1